Dupixent Skin Cancer Attorneys

Man scratching irritated skin on arm

Dupixent and Cutaneous T-Cell Lymphoma (CTCL)

What is Dupixent?

Dupixent (dupilumab) is a prescription medication that has been widely used since its FDA approval in 2017. Marketed as a breakthrough treatment, it is prescribed for:

  • Moderate to severe eczema (atopic dermatitis)
  • Asthma not well controlled by inhalers
  • Chronic rhinosinusitis with nasal polyps

The drug works by blocking certain proteins in the immune system, reducing inflammation that contributes to these chronic conditions. For many patients, Dupixent has provided meaningful relief where other treatments failed.

However, safety concerns have recently surfaced. Reports suggest that some patients who used Dupixent developed a rare and serious skin cancer known as cutaneous T-cell lymphoma (CTCL).

Reported Risks & Side Effects

Like most medications, Dupixent carries known side effects such as:

  • Eye irritation or conjunctivitis
  • Injection site reactions
  • Cold sores on the lips or mouth

But what makes the emerging risk of CTCL different is its severity. CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin. Symptoms may include:

  • Persistent red or scaly patches that resemble eczema or psoriasis
  • Raised plaques or nodules on the skin
  • Itching or discomfort that does not improve with standard treatments

Because CTCL often mimics other skin conditions, it may go undiagnosed until it has progressed. For patients already being treated for eczema with Dupixent, this overlap can delay proper diagnosis.

Ongoing investigations are raising questions about whether the manufacturer adequately warned patients and physicians about this potential risk.

Who May Be Affected

Ward Black Law is currently investigating claims for individuals who:

  • Used Dupixent for at least one month
  • Were diagnosed with cutaneous T-cell lymphoma (CTCL)
  • Did not have a prior diagnosis of Hodgkin lymphoma, non-Hodgkin lymphoma, non-follicular lymphoma, or leukemia

If this describes you or a loved one, speaking with a Dupixent attorney can help you understand your options and whether you may be eligible to pursue a claim.

Understanding Cutaneous T-Cell Lymphoma (CTCL)

At Ward Black Law, we are committed to helping individuals and families affected by dangerous drugs and unexpected diagnoses. If you have questions about Dupixent and CTCL, a Dupixent attorney from our team can:

  • Listen to your story and provide clear, straightforward answers
  • Explain what ongoing investigations may mean for you
  • Help you explore whether you may be eligible for a claim

Our goal is to stand with those facing life-changing diagnoses and ensure their voices are heard.

Frequently Asked Questions

Is Dupixent still being prescribed?
Yes. Dupixent is still prescribed for eczema, asthma, and sinus conditions. Investigations are ongoing to determine if patients are being fully informed about all potential risks.

Does every Dupixent patient qualify for a claim?
No. Claims are being reviewed specifically for individuals who used Dupixent and were later diagnosed with CTCL, without prior diagnoses of other cancers such as Hodgkin or non-Hodgkin lymphoma.

Why should I speak with a Dupixent attorney?
A Dupixent attorney can review your situation, help you understand your options, and guide you through the next steps if you may qualify for a claim.

What does it cost to find out if I qualify?
Nothing. Ward Black Law offers a free case review to help you determine whether you may be eligible.

Take the Next Step

If you or someone you love developed cutaneous T-cell lymphoma after using Dupixent, you don’t have to face the uncertainty alone. Speaking with a Dupixent attorney can help you understand the ongoing investigations and whether you may qualify to move forward with a claim.

Call, text, or email Ward Black Law today for a free case review.